Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články, pozorovací studie, práce podpořená grantem
PubMed
26678853
DOI
10.1007/s00280-015-2936-z
PII: 10.1007/s00280-015-2936-z
Knihovny.cz E-zdroje
- Klíčová slova
- Kinetic targeting, Pegylated liposomal doxorubicin, Plasmafiltration,
- MeSH
- dospělí MeSH
- doxorubicin aplikace a dávkování škodlivé účinky analogy a deriváty krev farmakokinetika MeSH
- hemofiltrace škodlivé účinky metody MeSH
- kritické orgány MeSH
- lidé středního věku MeSH
- lidé MeSH
- metabolická clearance MeSH
- nádory vaječníků * farmakoterapie patologie MeSH
- nádory vejcovodů * farmakoterapie patologie MeSH
- nežádoucí účinky léčiv etiologie prevence a kontrola MeSH
- plocha pod křivkou MeSH
- poločas MeSH
- polyethylenglykoly aplikace a dávkování škodlivé účinky farmakokinetika MeSH
- progrese nemoci MeSH
- protinádorová antibiotika aplikace a dávkování škodlivé účinky krev farmakokinetika MeSH
- senioři MeSH
- staging nádorů MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
- práce podpořená grantem MeSH
- Názvy látek
- doxorubicin MeSH
- liposomal doxorubicin MeSH Prohlížeč
- polyethylenglykoly MeSH
- protinádorová antibiotika MeSH
PURPOSE: To examine the removal of pegylated liposomal doxorubicin (PLD) during plasmafiltration (PF) and determine whether the drug could be withheld prior to its organ distribution responsible for mucocutaneous toxicity. METHODS: Six patients suffering from platinum-resistant ovarian cancer were treated with a 1-h IV infusion 50 mg/m(2) of PLD/cycle-for three cycles q4w. Over 44 (46)-47(49) h postinfusion, five patients (14 cycles in total) underwent PF using a cascade PF method consisted of plasma separation by centrifugation and plasma treatment using filtration based one volume of plasma treatment, i.e., 3.18 L (±0.6 L) and plasma flow 1.0 L/h (0.91-1.48 L/h). Doxorubicin concentration in blood was monitored by a high-performance liquid chromatography method for 116 h postinfusion. Pharmacokinetic parameters determined from plasma concentration included volume of distribution, total body clearance, half-life of elimination, and area under the plasma concentration versus time. The amount of doxorubicin in the body eliminated by the patient and via extracorporeal treatment was evaluated. Toxicity was tested using CTCAE v4.0. RESULTS: The efficacy of PF and early responses to PLD/PF combination strategy were as follows: over 44(46) h postinfusion considered necessary for target distribution of PLD to tumor, patients eliminated 46 % (35-56 %) of the dose administered. Over 44(46)-47(49) h postinfusion, a single one-volume plasma filtration removed 40 % (22-45 %) (Mi5) of the remaining doxorubicin amount in the body. Total fraction eliminated attained 81 % (75-86 %). The most common treatment-related adverse events (grade 1-2) such as nausea (4/14 cycles-28 %) and vomiting (3/14 cycles-21 %) appeared during 44 h postinfusion. Hematological toxicity-anemia (5/14 cycles-35 %) was reported after cycle II termination. Symptoms of PPE-like syndrome (grade 1-2) appeared in one patient concomitantly with thrombophlebitis and malignant effusion. In this study, only one adverse reaction (1/14-7 %) as short-term malaise and nausea was reported by the investigator as probably related to PF. CONCLUSION: A single one-volume PF does remove a clinically important amount of doxorubicin in a kinetic targeting approach. There were no serious signs of drug toxicity and/or PF-related adverse events. Kinetically guided therapy with pegylated liposomal doxorubicin combined with PF may be a useful tool to the higher efficacy and tolerability of therapy with PLD.
Citace poskytuje Crossref.org
